Fig. 1
From: Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
Mean difference in lipoprotein particle concentrations between evolocumab and palacebo group, adjusting for pre-treatment lipoprotein particle concentrations. Circles represent the posterior mean difference. Lines refer to the 95% credible intervals